Anzeige
Mehr »
Samstag, 18.10.2025 - Börsentäglich über 12.000 News
Europa rüstet Drohnenabwehr auf - und diese Aktie könnte die Technologie dazu liefern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHB | ISIN: US03828A1016 | Ticker-Symbol: 2UV
Tradegate
17.10.25 | 18:05
1,052 Euro
-3,71 % -0,041
1-Jahres-Chart
APPLIED THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APPLIED THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0701,11017.10.
1,0721,11317.10.

Aktuelle News zur APPLIED THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.09.Applied Therapeutics stock plunges after FDA meeting on CMT-SORD drug50
29.09.Applied Therapeutics meets with FDA on potential CMT-SORD drug37
APPLIED THERAPEUTICS Aktie jetzt für 0€ handeln
29.09.Applied Therapeutics Provides Update Following Meeting with FDA192NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for...
► Artikel lesen
29.08.Applied Therapeutics, Inc. - 8-K, Current Report34
14.08.Applied Therapeutics GAAP EPS of -$0.15 beats by $0.0127
13.08.Applied Therapeutics, Inc. - 10-Q, Quarterly Report9
13.08.Applied Therapeutics, Inc. - 8-K, Current Report6
13.08.Applied Therapeutics Reports Second Quarter 2025 Financial Results265- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE...
► Artikel lesen
17.06.Applied Therapeutics promotes two executives to leadership roles38
17.06.Applied Therapeutics Announces Key Leadership Appointments22
12.06.Applied Therapeutics, Inc. - 8-K, Current Report12
18.05.Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting445Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute...
► Artikel lesen
14.05.Applied Therapeutics GAAP EPS of -$0.15 beats by $0.0319
13.05.Applied Therapeutics, Inc. - 8-K, Current Report9
13.05.Applied Therapeutics Reports First Quarter 2025 Financial Results275- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society...
► Artikel lesen
09.05.Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting26
24.04.Applied Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans19
14.04.Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results307- Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025...
► Artikel lesen
19.03.Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer258NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced...
► Artikel lesen
20.12.24Applied Therapeutics Appoints John H. Johnson as Executive Chairman506Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc....
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,6,100